Bayer to Buy Conceptus for 11 Billion

Bayer to Buy Conceptus for $1.1 Billion

April 29, 2013
Company says it wants to broaden its portfolio in the field of contraception.

FRANKFURT -- Chemicals and pharmaceuticals giant Bayer (IW 1000/88) said Monday it has agreed to buy US women's healthcare specialist Conceptus for $1.1 billion.

"Bayer intends to broaden its portfolio in the field of contraception.  Bayer HealthCare LLC has therefore signed a merger agreement with Conceptus, Inc.," Bayer said..

California-based Conceptus developed the Essure procedure, a non-surgical permanent birth control method.

"With this acquisition, Bayer will be able to offer a complete range of short-term, long-term and permanent contraceptive choices for women," the German company said.

Bayer would launch a public tender offer "within the next ten business days to acquire all shares in Conceptus."

The deal was subject to anti-trust approval in the U.S. and was expected by mid 2013, Bayer said.

Copyright Agence France-Presse, 2013

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2024. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!